Clinica Medica, Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
J Hypertens. 2023 Nov 1;41(11):1688-1695. doi: 10.1097/HJH.0000000000003538. Epub 2023 Sep 4.
The present study aims to examine the effects of nonpharmacological, pharmacological and devices-based treatment on hypertension-related sympathetic overactivity. This will be done by analyzing the results of different published studies, in which sympathetic activity has been assessed via indirect or direct techniques. After examining the rationale for sympathomodulatory interventions in antihypertensive treatment, the study will discuss the methodological intrinsic limitations of the studies aimed at assessing different therapeutic interventions. The core of the study will be then focused on the effects of nonpharmacological (dietary restriction of sodium intake, physical exercise training, weight reduction), pharmacological (monotherapy, combination drug treatment, new drugs such as sodium glucose co-transport protein-2 inhibitors and angiotensin receptor neprilysin inhibitors), as well as devices-based interventions (renal sympathetic nerves ablation and carotid baroreceptor activation therapy) on the hypertension-related sympathetic overdrive. Finally, the areas worthy of future research as well as the debated issues in the field will be highlighted.
本研究旨在探讨非药物、药物和器械治疗对与高血压相关的交感神经活性过度的影响。这将通过分析不同已发表研究的结果来实现,这些研究通过间接或直接技术评估了交感神经活性。在检查了交感神经调节干预在抗高血压治疗中的基本原理之后,本研究将讨论旨在评估不同治疗干预措施的研究中的内在方法学局限性。研究的核心将集中在非药物治疗(限制钠摄入的饮食、体育锻炼训练、减肥)、药物治疗(单药治疗、联合药物治疗、新型药物如钠葡萄糖共转运蛋白 2 抑制剂和血管紧张素受体脑啡肽酶抑制剂)以及器械治疗(肾交感神经消融术和颈动脉压力感受器激活治疗)对与高血压相关的交感神经过度驱动的影响。最后,将强调未来研究值得关注的领域以及该领域存在争议的问题。